Is QMS Medical overvalued or undervalued?

As of 14 August 2025, the valuation grade for QMS Medical has moved from very attractive to attractive. The company is currently assessed as undervalued based on its financial ratios and peer comparisons. Key ratios include a PE Ratio of 12.50, an EV to EBITDA of 8.20, and a PEG Ratio of 0.63, which suggest that QMS Medical is trading at a discount relative to its earnings growth potential.
In comparison to its peers, QMS Medical's valuation appears favorable. For instance, Poly Medicure has a significantly higher PE Ratio of 53.86, while Blue Jet Health stands at 38.33. These comparisons highlight that QMS Medical is more attractively priced within the healthcare services sector. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date decline of 33.85% compared to a 4.17% increase in the index, reinforcing the notion that the stock may be undervalued relative to its intrinsic value.